Cyproheptadine

Evidence Level: L5

Predicted Indications: 1

Cyproheptadine

Pharmacist Assessment Report

Cyproheptadine: H1 antagonist and anticholinergic antihistamine → nasal cavity disease

One-Sentence Summary

Cyproheptadine is an antihistamine with anticholinergic activity, marketed in India as single-ingredient syrups, tablets and drops. The TxGNN model predicts it may be relevant for nasal cavity disease, but no clinical trials and no publications were found to support this direction, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	nasal cavity disease
TxGNN Prediction Score	0.9921
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, cyproheptadine blocks histamine H1 receptors and has anticholinergic effects. Both actions are relevant to nasal symptoms such as congestion, sneezing and watery discharge.

“Nasal cavity disease” is a broad, non-specific category. The high model score most likely reflects the drug’s pharmacological relevance to allergic and vasomotor nasal conditions rather than a specific, testable disease. No specific literature or trial evidence exists for a defined nasal cavity condition, so this is a prediction only. A specific disease entity (for example allergic rhinitis, or chronic rhinosinusitis) should be defined before any evaluation.

Similarity to existing uses and route compatibility have not yet been assessed.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

The drug is marketed in India. The data compiled for this report show 20 valid single-ingredient licences and no cancelled ones; this list may be partial. No approved-indication text is recorded for these licences. Dosage forms include syrup, tablets, drops and oral suspension.

Authorization Number	Product Name	Dosage Form	Approved Indication
41285	Ceron Syrup	Bottle of 200 ml syrup	Not recorded
34969	Colactin Syrup	Bottle of 200 ml syrup	Not recorded
118282	Kardine Syrup	Bottle of 200 ml syrup	Not recorded
57658	Cypnid 4mg Tablet	Strip of 10 tablets	Not recorded
105795	Hysin 1.5 mg/55 mg Drop	Packet of 30 ml drop	Not recorded

Safety Considerations

Drug Interactions: 308 interactions were identified in total. Major-level interactions include potassium chloride and potassium citrate. Moderate-level interactions are mainly with other anticholinergic agents (atropine, hyoscyamine, scopolamine, glycopyrronium, dicyclomine, trospium) and with central nervous system or gut-motility agents (morphine, opium, loperamide, dronabinol, nabilone, metoclopramide, eluxadoline, fenfluramine).

Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score (0.9921) but no supporting trials or publications, and the predicted term is too broad to evaluate. The evidence level is L5.

To proceed, the following is needed:

Define a specific nasal cavity disease entity for evaluation
Mechanism of action data
Package insert warnings and contraindications from the Indian regulator
A literature and trial search for the defined condition
Assessment of route compatibility (for example oral versus nasal use)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.